Home › Categories › Business & Finance› HHS-FDA-22-0115

HHS-FDA-22-0115.pdf

🔗 Source: americanoversight.org

📊 Size: 231 KB

📄 Pages: 7 pages

⬇️ Downloads: 72

Summary

American Oversight submitted a Freedom of Information Act (FOIA) request to the FDA, seeking records related to the approval of Biogen's Alzheimer's drug Aduhelm (aducanumab). The request follows the FDA's accelerated approval of the drug despite a negative recommendation from its advisory committee. American Oversight requests email communications between FDA officials and external entities, including Biogen, from September 1, 2020, to June 7, 2021. The request aims to shed light on the FDA's approval process and potential interactions between the agency and Biogen. A fee waiver is also requested, citing the public interest in understanding the government's operations and the significant impact of the FDA's decision on the public.

Download File

Description

American Oversight submitted a Freedom of Information Act (FOIA) request to the FDA, seeking records related to the approval of Biogen's Alzheimer's drug...

Technical Information

File Format: PDF
File Size: 231 KB
Pages: 7
Language: EN
Total Downloads: 72
Last Updated: 1 week ago

Document Overview

This PDF document about HHS-FDA-22-0115 provides comprehensive information and guidance. Whether you're a beginner or advanced user, this resource offers valuable insights into HHS-FDA-22-0115.